ATE20185T1 - Mittel zur verhuetung und behandlung von leberund nierenkrankheiten. - Google Patents

Mittel zur verhuetung und behandlung von leberund nierenkrankheiten.

Info

Publication number
ATE20185T1
ATE20185T1 AT82107092T AT82107092T ATE20185T1 AT E20185 T1 ATE20185 T1 AT E20185T1 AT 82107092 T AT82107092 T AT 82107092T AT 82107092 T AT82107092 T AT 82107092T AT E20185 T1 ATE20185 T1 AT E20185T1
Authority
AT
Austria
Prior art keywords
liver
preventing
treatment
kidney diseases
agent
Prior art date
Application number
AT82107092T
Other languages
German (de)
English (en)
Inventor
Shigemi Fujisaki
Mitsuaki Mitani
Original Assignee
Kaken Pharma Co Ltd
Shigemi Fujisaki
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=14899442&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE20185(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kaken Pharma Co Ltd, Shigemi Fujisaki filed Critical Kaken Pharma Co Ltd
Application granted granted Critical
Publication of ATE20185T1 publication Critical patent/ATE20185T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21081—Streptogrisin B (3.4.21.81)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT82107092T 1981-08-10 1982-08-05 Mittel zur verhuetung und behandlung von leberund nierenkrankheiten. ATE20185T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP56125002A JPS5826822A (ja) 1981-08-10 1981-08-10 慢性腎炎治療剤
EP82107092A EP0072947B2 (en) 1981-08-10 1982-08-05 Agent for the prevention and treatment of liver diseases

Publications (1)

Publication Number Publication Date
ATE20185T1 true ATE20185T1 (de) 1986-06-15

Family

ID=14899442

Family Applications (1)

Application Number Title Priority Date Filing Date
AT82107092T ATE20185T1 (de) 1981-08-10 1982-08-05 Mittel zur verhuetung und behandlung von leberund nierenkrankheiten.

Country Status (7)

Country Link
US (1) US4485095A (en])
EP (1) EP0072947B2 (en])
JP (1) JPS5826822A (en])
AT (1) ATE20185T1 (en])
AU (1) AU558711B2 (en])
DD (1) DD202804A5 (en])
DE (1) DE3271549D1 (en])

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4844897A (en) * 1985-09-13 1989-07-04 Hiroshi Maeda Anti-tumor protease preparations
JPS62215533A (ja) * 1986-03-17 1987-09-22 Shigemi Fujisaki 膠原病又は関節リウマチの予防治療剤
JPS61293928A (ja) * 1986-06-18 1986-12-24 Kaken Pharmaceut Co Ltd 腎ネフロ−ゼ治療剤
EP0309602B1 (de) * 1987-09-30 1993-03-24 MUCOS EMULSIONSGESELLSCHAFT m.b.H. Verwendung katabolischer Enzyme zur Herstellung eines Medikaments zum Bekämpfen der erworbenen Immunschwäche (AIDS) und deren Vorstadien (LAS, ARC)
JP3054190B2 (ja) 1989-01-27 2000-06-19 イムノリティックス・インコーポレイテッド 良性前立腺肥大処置のための組成物および方法
US5116615A (en) * 1989-01-27 1992-05-26 Immunolytics, Inc. Method for treating benign prostatic hypertrophy
JPH02292226A (ja) * 1989-05-08 1990-12-03 Shigemi Fujisaki 障害された神経細胞賦活予防治療剤
NL9201842A (nl) * 1992-10-23 1994-05-16 Teng Hian Khoe Toepassing van een papaine bevattend voedingssupplement voor therapeutische behandeling van AIDS aandoeningen.
US5639934A (en) * 1993-04-01 1997-06-17 Nakamichi Yamasaki Process for the desulfurization of sulfur-containing compositions by hydrothermal reaction
JP2673417B2 (ja) * 1994-08-03 1997-11-05 茂巳 藤崎 Ｂ型肝炎又はｃ型肝炎のウイルス性疾患の予防治療剤
US5814328A (en) 1997-01-13 1998-09-29 Gunasekaran; Subramanian Preparation of collagen using papain and a reducing agent
US20020102253A1 (en) * 1997-02-25 2002-08-01 Mynott Tracey Lehanne Component of bromelain
DE19726253C2 (de) * 1997-06-20 2000-03-16 Mucos Pharma Gmbh & Co Verwendung von mindestens einem proteolytischen Enzym und Rutosid zur Behandlung von Glomerulonephritis
GB9713667D0 (en) * 1997-06-27 1997-09-03 Cortecs Ltd Enhancement of intestinal permeability
JP2002087990A (ja) * 2000-09-18 2002-03-27 Shigemi Fujisaki エイズ、ｂ型肝炎、ｃ型肝炎、インフルエンザなどのウイルス性疾患予防治療剤
WO2003066088A2 (de) * 2002-02-06 2003-08-14 Trommsdorff Gmbh & Co. Kg Arzneimittel Protease-screening und neue verwendung von proteasen
AUPS242702A0 (en) * 2002-05-21 2002-06-13 Colltech Australia Limited Improved method for the extraction and purification of collagen
US8710012B2 (en) 2003-07-14 2014-04-29 Cls Therapeutics Limited Method for treating oncological diseases
US8388951B2 (en) 2003-07-14 2013-03-05 Cls Therapeutics Limited Method for treating systemic DNA mutation disease
US8431123B2 (en) 2003-07-14 2013-04-30 Cls Therapeutics Limited Method for treating systemic bacterial, fungal and protozoan infection
AU2004285558A1 (en) * 2003-10-29 2005-05-12 Altus Pharmaceuticals Inc. Non-pancreatic proteases for controlling plasma cholecystokinin (CCK) concentration and for treating pain
US8916151B2 (en) * 2005-04-25 2014-12-23 Cls Therapeutics Limited Method for treating a reduction of fertility
WO2008066403A1 (en) * 2006-11-28 2008-06-05 Dmitry Dmitrievich Genkin Method for treating human diseases associated with an increased deoxyribonucleic acid content in extracellular spaces of tissues and a medicinal preparation for carrying out said method
UA28103U (uk) 2007-07-12 2007-11-26 Ольга Олександрівна Біляєва Комплексний сорбційно-протеолітичний препарат сертасил для лікування гнійних ран, трофічних виразок, опіків
WO2010079209A2 (en) * 2009-01-08 2010-07-15 Golub Alexandr A Compositions for treating wounds and skin conditions
US10086053B2 (en) 2012-12-06 2018-10-02 Giuseppe CARPIGNOLI Therapeutic vegetable substances
ITTO20121050A1 (it) * 2012-12-06 2014-06-07 Giuseppe Carpignoli Sostanze vegetali ad effetto curativo
US10617743B2 (en) 2014-06-19 2020-04-14 Cls Therapeutics Limited Method to improve safety and efficacy of anti-cancer therapy
ES2799515T3 (es) 2015-05-22 2020-12-18 Dmitry Dmitrievich Genkin ADN extracelular como una diana terapéutica en la neurodegeneración
US11905522B2 (en) 2018-01-16 2024-02-20 Cls Therapeutics Limited Treatment of diseases by liver expression of an enzyme which has a deoxyribonuclease (DNase) activity

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2073659A (en) * 1933-12-13 1937-03-16 Ernest K Stratton Medicinal compounds
US3004893A (en) * 1959-10-21 1961-10-17 Richardson Merrell Inc Enteric coated trypsin and chymotrypsin anti-inflammatory compositions
FR2603M (fr) * 1962-01-22 1964-06-22 Roussel Uclaf Nouveau médicament notamment pour le traitement des dégénérescences hépatiques d'origine chimique, bactérienne, toxique ou sénile.
US3324002A (en) * 1962-09-17 1967-06-06 Armour Pharma Anti-inflammatory preparations containing proteolytic enzymes and adrenal glucocorticoids
FR3536M (en]) * 1964-06-16 1965-09-13 Mauvernay Roland Yves
BE684147A (en]) * 1965-07-22 1966-12-16
LU59502A1 (en]) * 1969-09-24 1970-02-26
US3819830A (en) * 1971-07-01 1974-06-25 Dainippon Pharmaceutical Co Method for treating diseases by coenzyme a and adenosine triphosphate and composition therefor
FR2448903A1 (fr) * 1979-02-19 1980-09-12 Martin Henri Medicament nouveau a base d'agents antimicrobiens, d'enzymes, d'anti-inflammatoires, d'anesthesique local, d'agents keratolytiques, d'agents mucolytiques et d'au moins un emulsionnant

Also Published As

Publication number Publication date
EP0072947A2 (en) 1983-03-02
EP0072947A3 (en) 1983-07-27
DE3271549D1 (en) 1986-07-10
JPH0133085B2 (en]) 1989-07-11
DD202804A5 (de) 1983-10-05
JPS5826822A (ja) 1983-02-17
AU558711B2 (en) 1987-02-05
EP0072947B1 (en) 1986-06-04
AU8579282A (en) 1983-02-17
EP0072947B2 (en) 1994-01-12
US4485095A (en) 1984-11-27

Similar Documents

Publication Publication Date Title
ATE20185T1 (de) Mittel zur verhuetung und behandlung von leberund nierenkrankheiten.
DE3579113D1 (de) Zusammensetzungen zur milderung, behandlung und bestimmungung von arthritschen krankheiten und aehnlichen zustaenden.
DE69826695D1 (de) Arylharnstoffderivate zur behandlung von inflammatorischen oder immunomodulatorischen erkrankungen
EP0792156A4 (en) Methods for the prevention or treatment of vascular hemorrhaging and alzheimer's disease
ATE126441T1 (de) Pentigetide zur behandlung von nicht-ige- vermittelten entzündlichen erkrankungen.
DE69434511D1 (de) Botulinumtoxin zur Behandlung von Dystonie
ATE31670T1 (de) Verfahren zur behandlung von verpackungsmaterial und das dementsprechend behandelte material.
DE69432299D1 (de) Multiple Botulinum Toxine zur Behandlung von neuromuskulären Störungen und Zuständen
ATE311853T1 (de) Verwendung von krillenzymen zur behandlung von zahnbelag
DE3884200D1 (de) Verfahren zur Behandlung von Mastitis und anderen Staphylokokkeninfektionen.
ATE974T1 (de) Mittel und verfahren zur behandlung und verbesserung des aussehens von textilien.
ATE196083T1 (de) Verwendung von ferrioxamin-b zur behandlung septischen schocks
DE69429101D1 (de) Verbindungen und zusammensetzungen zur behandlung von allergien und entzündungen
DE3854121D1 (de) Arzneimittelzusammensetzungen zur behandlung von psoriasis.
ATE273011T1 (de) Zusammensetzung und verfahren zur behandlung von herpes simplex
ATE116850T1 (de) Mittel zur behandlung von erkrankungen der venen und des analbereichs.
DE59813914D1 (de) Mittel zur behandlung und/oder prophylaxe von mikrozirkulationsstörungen
ATE208202T1 (de) Verwendung von dimeticon zur behandlung der konstipation
DE69534761D1 (de) Zusammensetzungen zur behandlung und vorbeugung von atherosklerose
LU84488A1 (de) Mittel zur behandlung von akne
DE3881377D1 (de) Mittel zur prophylaxe und behandlung von thrombocytopenie.
DE3585312D1 (de) Anwendung von 1,6-dimethyl-4-oxo-1,6,7,8,9a-hexahydro-4h-pyrido(1,2-a)pyrimidin-3-carboxamid zur vorbeugung und behandlung von gastrointestinalschaeden.
ATE63812T1 (de) Mittel zur behandlung von erkrankungen der venen und des analbereichs.
ATE55252T1 (de) Zusammensetzungen zur milderung, behandlung und bestimmungung von arthritschen krankheiten und aehnlichen zustaenden.
ATE63457T1 (de) Arzneimittel zur behandlung und prophylaxe von leber- und nierenkrankheiten.